Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Esperion Therapeutics nets $74.9mm with its second IPO

Executive Summary

Cardiometabolic drug developer Esperion Therapeutics Inc. has netted $74.9mm through its initial public offering of 5.75mm common shares (including the overallotment) at $14, the midpoint of its proposed $13-15 range. Certain existing shareholders and affiliated entities bought a total of 1.2mm of the shares.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies